Evaluation du site parexel.com
CRO & Biopharmaceutical Services | Parexel
Généré le 07 Mars 2026 21:15
Vieilles statistiques? UPDATE !
Le score est de 60/100
Optimisation du contenu
Titre
CRO & Biopharmaceutical Services | Parexel
Longueur : 42
Parfait, votre titre contient entre 10 et 70 caractères.
Description
For over 35 years Parexel has been a trusted global CRO and biopharmaceutical services company. Learn more about how we can help.
Longueur : 129
Génial, votre balise META description contient entre 70 et 160 caractères.
Mots-clefs
biopharmaceutical services
Bien, votre page contient une balise META keywords.
Propriétés Open Graph
Cette page ne profite pas des balises META Open Graph. Cette balise permet de représenter de manière riche n'importe quelle page dans le graph social (environnement social). Utilisez ce générateur gratuit de balises META Open Graph pour les créer.
Niveaux de titre
| H1 | H2 | H3 | H4 | H5 | H6 |
| 1 | 2 | 51 | 8 | 32 | 0 |
- [H1] Who we are,
- [H2] While running a triathlon, Andrea stumbled and realized something was wrong.
- [H2] Parexel is proudly among the world’s largest clinical research organizations
- [H3] Solutions
- [H3] Portfolio management and asset valuation
- [H3] Early development and innovation
- [H3] Integrated clinical development
- [H3] Approval and access
- [H3] Value substantiation lifecycle management
- [H3] Operational excellence
- [H3] Biotech
- [H3] Therapeutic Expertise
- [H3] General medicine
- [H3] Infectious disease and vaccines
- [H3] Immunology
- [H3] Oncology
- [H3] Neuroscience
- [H3] Hematology
- [H3] Insights
- [H3] Participate
- [H3] Patient volunteers
- [H3] Sites
- [H3] About
- [H3] Leadership team
- [H3] Compliance, tax & privacy
- [H3] Solutions
- [H3] Portfolio management and asset valuation
- [H3] Early development and innovation
- [H3] Integrated clinical development
- [H3] Approval and access
- [H3] Value substantiation lifecycle management
- [H3] Operational excellence
- [H3] Biotech
- [H3] Therapeutic Expertise
- [H3] General medicine
- [H3] Infectious disease and vaccines
- [H3] Immunology
- [H3] Oncology
- [H3] Neuroscience
- [H3] Hematology
- [H3] Insights
- [H3] Participate
- [H3] Patient volunteers
- [H3] Sites
- [H3] About
- [H3] Leadership team
- [H3] Compliance, tax & privacy
- [H3] She thought it was just an injury. Her hamstrings were tight, and her body felt stiff and slow.
- [H3] She had ALS, a condition affecting more than 200,000 people around the world.
- [H3] Her life expectancy was shortened to just two to five years — but she was determined to make the most of it.
- [H3] Andrea continued to join triathlons, even as she underwent treatment in a clinical trial, inspiring many and raising $1,000,000 for ALS research.
- [H3] Today, alive beyond her original prognosis, she serves on our Patient Advisory Council, using her experiences to help improve our neuroscience trials.
- [H3] Lives can change when you design neuroscience trials with speed and precision.
- [H3] We focus on patients, because they inspire us to deliver better trials, faster than ever. So we can make a difference for more patients everywhere.
- [H4]
- [H4] Oncology
- [H4] I&I
- [H4] Cell & Gene Therapy
- [H4] Endocrine & Metabolic
- [H4] Resources
- [H4] Regional Websites
- [H4] Quick Links
- [H5] WHAT WE DO
- [H5] HOW WE DO IT
- [H5] PODCAST
- [H5] THERAPEUTIC EXPERTISE
- [H5] CROSS-THERAPEUTIC EXPERTISE
- [H5] RELATED INSIGHTS
- [H5] NEW MEDICINES, NOVEL INSIGHTS
- [H5] FEATURED INSIGHTS
- [H5] RECENT INSIGHTS
- [H5]
- [H5] Biopharm workforce report
- [H5] Powered by people
- [H5] INTERESTED IN PARTICIPATING?
- [H5] TRIAL SITES
- [H5] HEAR FROM REAL PATIENTS
- [H5] AWARD-WINNING-PARTNERS
- [H5] WHAT WE DO
- [H5] HOW WE DO IT
- [H5] PODCAST
- [H5] THERAPEUTIC EXPERTISE
- [H5] CROSS-THERAPEUTIC EXPERTISE
- [H5] RELATED INSIGHTS
- [H5] NEW MEDICINES, NOVEL INSIGHTS
- [H5] FEATURED INSIGHTS
- [H5] RECENT INSIGHTS
- [H5]
- [H5] Biopharm workforce report
- [H5] Powered by people
- [H5] INTERESTED IN PARTICIPATING?
- [H5] TRIAL SITES
- [H5] HEAR FROM REAL PATIENTS
- [H5] AWARD-WINNING-PARTNERS
Images
Nous avons trouvé 23 image(s) sur cette page Web.
Bien, la plupart ou la totalité de vos images possèdent un attribut alt
Ratio texte/HTML
Ratio : 24%
Bien, le ratio de cette page texte/HTML est supérieur à 15, mais inférieur à 25 pour cent.
Flash
Parfait, aucun contenu FLASH n'a été détecté sur cette page.
Iframe
Dommage, vous avez des Iframes sur vos pages Web, cela signifie que son contenu ne peut pas être indexé par les moteurs de recherche.
Liens
Réécriture d'URLs
Bien. Vos liens sont optimisés!
Tiret bas dans les URLs
Parfait! Aucuns soulignements détectés dans vos URLs.
Liens dans la page
Nous avons trouvé un total de 162 lien(s) dont 0 lien(s) vers des fichiers
| Texte d'ancre | Type | Juice |
|---|---|---|
| Solutions | Interne | Passing Juice |
| Portfolio management and asset valuation | Interne | Passing Juice |
| Early development and innovation | Interne | Passing Juice |
| Integrated clinical development | Interne | Passing Juice |
| Approval and access | Interne | Passing Juice |
| Value substantiation lifecycle management | Interne | Passing Juice |
| Delivery models | Interne | Passing Juice |
| Operational excellence | Interne | Passing Juice |
| Medical affairs | Interne | Passing Juice |
| Study start-up | Interne | Passing Juice |
| Overview | Interne | Passing Juice |
| Building patient insights into assets, profile and claims | Interne | Passing Juice |
| Portfolio optimization | Interne | Passing Juice |
| Asset valuation and indication prioritization | Interne | Passing Juice |
| Early evidence review | Interne | Passing Juice |
| Integrated development strategy and planning | Interne | Passing Juice |
| Phase I Clinical Trials | Interne | Passing Juice |
| Site Alliance Network and KOL Engagement | Interne | Passing Juice |
| Quantitative Clinical Pharmacology and Model-Informed Drug Development (MIDD) | Interne | Passing Juice |
| Regulatory Strategy | Interne | Passing Juice |
| Real World Evidence | Interne | Passing Juice |
| Market Access Consulting, Strategy, and Delivery | Interne | Passing Juice |
| Biomarker and Genomic Medicine Strategy | Interne | Passing Juice |
| Integrated evidence generation planning | Interne | Passing Juice |
| Medical Communications | Interne | Passing Juice |
| Phase IIB-IV Clinical Trials | Interne | Passing Juice |
| Real World Evidence | Interne | Passing Juice |
| Quantitative Clinical Pharmacology and Model-Informed Drug Development (MIDD) | Interne | Passing Juice |
| Protocol-Driven, Customized Site Solution Strategy | Interne | Passing Juice |
| Patient Inclusion | Interne | Passing Juice |
| Regulatory Strategy, Submissions, Compliance, and Outsourcing | Interne | Passing Juice |
| Market Access Strategy and Delivery | Interne | Passing Juice |
| Clinical Development Technology Optimization | Interne | Passing Juice |
| Clinical Trial Supply & Logistics | Interne | Passing Juice |
| Integrated evidence generation planning | Interne | Passing Juice |
| Medical Communications | Interne | Passing Juice |
| Drug Safety and Pharmacovigilance | Interne | Passing Juice |
| Global Regulatory Submissions and Outsourcing | Interne | Passing Juice |
| Real World Evidence | Interne | Passing Juice |
| Compliance and Risk Management | Interne | Passing Juice |
| Market Access Strategy and Delivery | Interne | Passing Juice |
| Integrated evidence generation planning | Interne | Passing Juice |
| Medical Communications | Interne | Passing Juice |
| Drug Safety and Pharmacovigilance | Interne | Passing Juice |
| Health economics modelling and simulation | Interne | Passing Juice |
| Real-World Evidence, Market Access Strategy and Planning | Interne | Passing Juice |
| Regulatory Compliance | Interne | Passing Juice |
| Lifecycle Optimization | Interne | Passing Juice |
| Integrated evidence generation planning | Interne | Passing Juice |
| Medical Communications | Interne | Passing Juice |
| Gain an advantage through FSP | Interne | Passing Juice |
| Leveraging AI in clinical development | Interne | Passing Juice |
| Medical affairs for clinical trials | Interne | Passing Juice |
| Biotech | Interne | Passing Juice |
| Listen Now | Interne | Passing Juice |
| Therapeutic Expertise | Interne | Passing Juice |
| Neuroscience | Interne | Passing Juice |
| General medicine | Interne | Passing Juice |
| Infectious disease and vaccines | Interne | Passing Juice |
| Immunology | Interne | Passing Juice |
| Oncology | Interne | Passing Juice |
| Hematology | Interne | Passing Juice |
| Cell and gene therapies | Interne | Passing Juice |
| Pediatrics | Interne | Passing Juice |
| Rare diseases | Interne | Passing Juice |
| Overview | Interne | Passing Juice |
| Cell and gene therapy | Interne | Passing Juice |
| Gastroenterology CRO | Interne | Passing Juice |
| Respiratory CRO | Interne | Passing Juice |
| Endocrine & Metabolic CRO | Interne | Passing Juice |
| Cardiovascular CRO | Interne | Passing Juice |
| Women's health CRO | Interne | Passing Juice |
| Critical Care | Interne | Passing Juice |
| Hepatitis B | Interne | Passing Juice |
| Novel treatments in infectious disease | Interne | Passing Juice |
| Ophthalmology CRO | Interne | Passing Juice |
| Dermatology CRO | Interne | Passing Juice |
| Allergy CRO | Interne | Passing Juice |
| Bladder cancer CRO | Interne | Passing Juice |
| Breast cancer CRO | Interne | Passing Juice |
| Gynecologic cancer CRO | Interne | Passing Juice |
| Head and neck cancer CRO | Interne | Passing Juice |
| Lung cancer CRO | Interne | Passing Juice |
| Phase I and rare tumors | Interne | Passing Juice |
| Prostate cancer CRO | Interne | Passing Juice |
| Neurology | Interne | Passing Juice |
| Psychiatry | Interne | Passing Juice |
| Pediatrics | Interne | Passing Juice |
| Rare Diseases | Interne | Passing Juice |
| Lymphoma CRO | Interne | Passing Juice |
| Acute myelogenous leukemia (AML) CRO | Interne | Passing Juice |
| Myelodysplastic syndrome (MDS) CRO | Interne | Passing Juice |
| Multiple Myeloma CRO | Interne | Passing Juice |
| Learn more | Interne | Passing Juice |
| Learn more | Interne | Passing Juice |
| Insights | Interne | Passing Juice |
| New frontiers in neuroscience | Interne | Passing Juice |
| Precision oncology | Interne | Passing Juice |
| Rare disease drug development | Interne | Passing Juice |
| Cell and gene therapy development | Interne | Passing Juice |
| Patient-guided drug development | Interne | Passing Juice |
| Clinical Trialblazers Podcast | Interne | Passing Juice |
| The Regulatory Navigator | Interne | Passing Juice |
| On The Pulse | Interne | Passing Juice |
| Learn more | Interne | Passing Juice |
| Learn more | Interne | Passing Juice |
| Participate | Interne | Passing Juice |
| Healthy volunteers | Interne | Passing Juice |
| Patient volunteers | Interne | Passing Juice |
| Patient advocacy groups | Interne | Passing Juice |
| Baltimore | Externe | Passing Juice |
| Los Angeles | Externe | Passing Juice |
| London | Externe | Passing Juice |
| Berlin | Externe | Passing Juice |
| Overview | Interne | Passing Juice |
| Advisory Council | Interne | Passing Juice |
| Patient stories | Interne | Passing Juice |
| Andrea & David's Story | Interne | Passing Juice |
| Stacy's Story | Interne | Passing Juice |
| Anisha's Story | Interne | Passing Juice |
| Rob's Story | Interne | Passing Juice |
| Learn more | Interne | Passing Juice |
| Sites | Interne | Passing Juice |
| Learn more | Interne | Passing Juice |
| About | Interne | Passing Juice |
| Leadership team | Interne | Passing Juice |
| Global reach | Interne | Passing Juice |
| Our inclusion strategy | Interne | Passing Juice |
| Our ESG strategy | Interne | Passing Juice |
| Compliance, tax & privacy | Interne | Passing Juice |
| Meet us at an event | Interne | Passing Juice |
| Overview | Interne | Passing Juice |
| Board of Directors | Interne | Passing Juice |
| Our ESG strategy | Interne | Passing Juice |
| Compliance & Ethics | Interne | Passing Juice |
| Tax Strategy | Interne | Passing Juice |
| Privacy Policy | Interne | Passing Juice |
| Cookies and other web tracking | Interne | Passing Juice |
| Supplier Data Privacy Requirements | Interne | Passing Juice |
| Terms of Use | Interne | Passing Juice |
| French Gender Pay Data | Interne | Passing Juice |
| UK Gender Pay Data | Interne | Passing Juice |
| UK Modern Slavery Act Statement | Interne | Passing Juice |
| Ireland Gender Pay Data | Interne | Passing Juice |
| Supplier Inclusion Policy | Interne | Passing Juice |
| Newsroom | Interne | Passing Juice |
| Academy | Externe | Passing Juice |
| Careers | Interne | Passing Juice |
| 中国 (China) | Interne | Passing Juice |
| 日本 (Japan) | Interne | Passing Juice |
| Contact Us | Interne | Passing Juice |
| Oncology | Interne | Passing Juice |
| Immunology | Interne | Passing Juice |
| Cell & Gene Therapy | Interne | Passing Juice |
| Endocrine & Metabolic | Interne | Passing Juice |
| See neuroscience capabilities | Interne | Passing Juice |
| Explore neuroscience careers | Interne | Passing Juice |
| biopharmaceutical leaders and sites | Interne | Passing Juice |
| Contact us | Interne | Passing Juice |
| My Communication Preferences | Interne | Passing Juice |
| Invoicing | Interne | Passing Juice |
| PO Terms and Conditions | Interne | Passing Juice |
Mots-clefs
Nuage de mots-clefs
more clinical development strategy patient access trials cro medical overview
Cohérence des mots-clefs
| Mot-clef | Contenu | Titre | Mots-clefs | Description | Niveaux de titre |
|---|---|---|---|---|---|
| clinical | 55 |  |
|
|
 |
| cro | 50 | |
|
|
|
| overview | 44 | |
|
|
|
| development | 36 | |
|
|
|
| strategy | 30 | |
|
|
|
Ergonomie
Url
Domaine : parexel.com
Longueur : 11
Favicon
Génial, votre site web dispose d'un favicon.
Imprimabilité
Aucun style CSS pour optimiser l'impression n'a pu être trouvé.
Langue
Bien. Votre langue est : en.
Dublin Core
Cette page ne profite pas des métadonnées Dublin Core.
Document
Doctype
HTML 5
Encodage
Parfait. Votre charset est UTF-8.
Validité W3C
Erreurs : 0
Avertissements : 0
E-mail confidentialité
Génial, aucune adresse e-mail n'a été trouvé sous forme de texte!
HTML obsolètes
Génial! Nous n'avons pas trouvé de balises HTML obsolètes dans votre code.
Astuces vitesse
|
Excellent, votre site n'utilise pas de tableaux imbriqués. |
|
Mauvais, votre site web utilise des styles css inline. |
|
Mauvais, votre site web contient trop de fichiers CSS (plus de 4). |
|
Mauvais, votre site web contient trop de fichiers javascript (plus de 6). |
|
Parfait : votre site tire parti de gzip. |
Mobile
Optimisation mobile
|
Icône Apple |
|
Méta tags viewport |
|
Contenu FLASH |
Optimisation
Sitemap XML
Votre site web dispose d’une sitemap XML, ce qui est optimal.
| https://www.parexel.com/sitemap.xml |
Robots.txt
https://parexel.com/robots.txt
Votre site dispose d’un fichier robots.txt, ce qui est optimal.
Mesures d'audience
Manquant
Nous n'avons trouvé aucun outil d'analytics sur ce site.
Un outil de mesure d'audience vous permet d'analyser l’activité des visiteurs sur votre site. Vous devriez installer au moins un outil Analytics. Il est souvent utile d’en rajouter un second, afin de confirmer les résultats du premier.
PageSpeed Insights
Dispositif
Les catégories
Free SEO Testing Tool
Free SEO Testing Tool est un outil gratuit de référencement qui vous aidera à analyser vos pages web